No Patient Left Behind

NPLB_org

~60% of paying customers across all 4 market segments hit @ahipcoverage plan barriers to care... This is bigger than poor NPS or CAHPS scores. @CMSGov @USDOL @SenSanders 👮‍♀️#PPACA oversight & fixes needed. https://t.co/Z3obSdKSq7

No Patient Left Behind

NPLB_org

@drugchannels @IQVIA_us 50%+ abandonment rate for ORAL cancer therapies w/OOP costs >$250 in Medicare is AWFUL. #IRA missed huge opportunity to eliminate Part D deductible altogether & set catastrophic cap lower than $2K so more than just 1M non-LIS benes helped in short term. https://t.co/d2JkM9bJ9p

No Patient Left Behind

NPLB_org

@RealClearHealth"Reform efforts only extend to MAPD benes. Until PBMs are paid only for their drug chain admin efforts, & not based on bogusly high drug prices & how much patients have to pay for them, we will still be struggling to get the meds we need." https://t.co/m5L7TDvQhF

No Patient Left Behind

NPLB_org

Insightful #BIO2023 @daphnezohar, @bradloncar, @JMaraganore @ColonGraceE & @DavidThomasCFA panel on state of biotech ecosystem. If discussion fired you up, consider joining 300+ R&D leaders & lend your name to help fix #IRA's 9-13 small molecule penalty: https://t.co/cu7cJmaqqy https://t.co/2WMe3rGYtr

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: Can anyone suggest a more engaging/polished way to teach the concepts here... about the value of medicines... and why…

No Patient Left Behind

NPLB_org

@steveusdin1 "IRA will cause [biotech] to delay launches of cancer drugs for smaller indications like mesothelioma & ovarian cancer to prioritize lung or prostate cancer. Patients will be harmed."Join biotech investors & innovators in support of 9➡️13 fix: https://t.co/cu7cJmaqqy https://t.co/zWwSfzw81F

No Patient Left Behind

NPLB_org

RT @thebiotechclub: Can we have affordable medicines for everyone? Join us over lunch to hear from @PeterKolchinsky, Founder of @NPLB_org…

No Patient Left Behind

NPLB_org

@UncoveredHealth shines light on how @cigna overutilizes prior authorization red tape to deny/delay patient care but underutilizes physicians to review PPACA-mandated customer/patient appeals. @CMSGov @USDOL @wendellpotter @loopcoalition https://t.co/HH3inuFg4O https://t.co/DeVATAYGxE

No Patient Left Behind

NPLB_org

First step toward updating faulty CEA math. @TuftsCEVR @PSynnott29 “CEA Registry to highlight that relatively few studies have included broader elements of value or life-cycle pricing.” @icer_review @CMSGov @NICEComms https://t.co/IrSx8Co7Fm

No Patient Left Behind

NPLB_org

@PeterNeumann11 @PSynnott29 @joeymattingly @brootmcq @PeterKolchinsky @drddawoud GCEA value flower is allergy free w/zero harmful side-effects!!!

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: I’m headed to #ISPORAnnual to talk about generalized cost-effectiveness analysis (GCEA). Investors like me try to unde…

No Patient Left Behind

NPLB_org

Happy Saturday morning cartoons! Click below to watch our GCEA animation. Find out what happens to patients, their caregivers, & society when health insurers tear off petals from the Rx value flower... @CMSGov @BrooksLaSureCMS @ISPORorg @TuftsCEVR @SchaefferCenter @drmeenasesh https://t.co/W6vF7TrVvi

No Patient Left Behind

NPLB_org

Yikes! Scary image of @nicecomms "toxic math" invading U.S. via @icer_review to shape @CMSGov IRA rules. Latest @RApport_bio @PeterKolchinsky Q&A w/J Dallas helps inoculate against faulty CEA math & highlights quantifiable patient/societal GCEA values NICE CEAs knowingly omit. https://t.co/WDwxe8p4Zv https://t.co/q03N8Ngu6r

No Patient Left Behind

NPLB_org

@CMSGov @CMSinnovates Beware of @NICEComms "toxic math" invading US benes MAPD Rx access via @icer_review's faulty math. @rapport_bio article from UK R&D head J Dallas & @PeterKolchinsky shares how we all lose when govt. & health plans ignore true value of Rx to patients/society https://t.co/EYALo6EFh1

No Patient Left Behind

NPLB_org

Thank you @ldtimmerman @DesertBiopharma @jmaxlevin @PeterKolchinsky for highlighting need to fix IRA. Easiest way for investors & innovators to help pitch in w/impact is to add your name to below call to action. https://t.co/cu7cJmaqqy https://t.co/dPcJ8r0DPO

No Patient Left Behind

NPLB_org

@patientsrising podcast listeners can learn more about how @icer_review & UK's @NICEComms use faulty cost-effectiveness (CEA) math to ignore the patient & societal value of medicines here: https://t.co/3MkjjBkrSP https://t.co/iqlFzfwtfH

No Patient Left Behind

NPLB_org

@DesertBiopharma "The [IRA] fix is straightforward: we need 13yrs for small molecules, as we have for biologics, for investors to continue supporting this area. It's not like small molecules cost less to develop or less risky to develop than biologics." https://t.co/JWAkFWXRtY

No Patient Left Behind

NPLB_org

@CMSGov @CMSinnovates @Kff Best way to fix MAPD plans from over-utilizing prior authorization to hassle sick patients & docs w/red tape is require $0 copay/coinsurance coverage when treatment eventually approved (by AI or human or doc). https://t.co/guuKL8ht0J

No Patient Left Behind

NPLB_org

W/o your voice, threat to biotech R&D remains. Policymakers representing the largest MA plans & PBMs want the govt. to set Rx prices @5yrs after approval w/o requiring new help to MA benes such as guaranteeing lower copays & deductibles or adding a $2000 Part B catastrophic cap.

No Patient Left Behind

NPLB_org

It is easy & free to stand up for the biotech ecosystem. Learn how #IRA already harming today's small molecule R&D decisions here. R&D should follow science, not partisan politics: https://t.co/L4RhNHCqjH

No Patient Left Behind

NPLB_org

RT @steveusdin1: The biopharma industry is planning a blizzard of litigation that could delay, modify, perhaps derail implementation of the…

No Patient Left Behind

NPLB_org

Fascinating @armandalegshow look @ how health care/insurance actually works. Lisa French was told she would have to pay $1,337 in OOP costs. Hospital sent her a bill for $229K. When she didn’t pay, the sheriff served her with a lawsuit & the hospital sued her (not the insurer). https://t.co/ZSZYBURm4T

No Patient Left Behind

NPLB_org

ICYMI: #White64 @NPLB_org's "Abbie" video that highlights impact of insurers high out-of-pocket costs on patients & their families was nominated by @TheOneClub as one of year's best. Reminder of why we fight for biotech affordability & innovation. https://t.co/2I7HzFUwlQ

No Patient Left Behind

NPLB_org

ICYMI: @NPLB_org's "Abbie" video that highlights impact of insurers high out-of-pocket costs on patients & their families nominated by @TheOneClub as one of the year's best. Important reminder about why we fight for biotech affordability & innovation. https://t.co/2I7HzFUwlQ

No Patient Left Behind

NPLB_org

"the simplified math that [CEA entities] use is a barrier to access when payors [Govts & insurers] use it as the reason they deny [patients] access [to prescribed treatments].. (eg @icer_review's framework ignores many demonstrable values, like fact that medicines go generic...)" https://t.co/BeiTESpYvl

No Patient Left Behind

NPLB_org

CMS IRA Rx "negotiation"/price-setting rule. Still time for biotech investors, innovators, researchers, & patients to submit public comments by EOD 4/14! Need help? Link to "how to" comment guide below. Don't let stakeholders say they never heard from you! https://t.co/xMMeoHPsS1

No Patient Left Behind

NPLB_org

RT @PearlF: I missed this the 1st or 2nd time it went around, but if your biopharma/biotech company is writing an email to CMS for Friday's…

No Patient Left Behind

NPLB_org

Mifepristone Ruling: Not too late to sign letter in support of FDA's Rx regulatory authority: https://t.co/Vlpf2qKFCq https://t.co/fHCVB4sWM0

No Patient Left Behind

NPLB_org

2) Join biotech investors, innovators, & patient advocates to prioritize fixing IRA so that it treats small & large molecule innovation equally. 1/2 of new FDA oncology drugs are small mol -- w/o fix, IRA makes war against cancer harder. Click link to sign https://t.co/ELYpm94u4d

No Patient Left Behind

NPLB_org

Mifepristone Ruling: Biotech leaders are gathering signatures for a one page letter (link to sign at bottom). https://t.co/Vlpf2qKFCq https://t.co/UF3oy5OYLP

No Patient Left Behind

NPLB_org

“Truth seeking independent bodies assimilate new information… political entities resist it. Which are you? @icer_review” https://t.co/vPQtehE5FR

No Patient Left Behind

NPLB_org

“Brazil is making the same mistakes other countries have when considering the value of medicines. They go generic and become public goods.” https://t.co/VzlZHX9hgR

No Patient Left Behind

NPLB_org

After reading @DesertBiopharma post-IRA small molecule R&D impact survey, please consider signing & sharing our innovators call to action. Biotech cannot defeat oncology when IRA effectively removed half the arrows in R&D quiver. https://t.co/PbPhIJHPM3 https://t.co/IJtQ3dlkcN

No Patient Left Behind

NPLB_org

Powerful @Carolynyjohnson reporting: how health plans (ab)use high OOP costs, prior auth, & red tape to deny premium-paying customers access to "covered" treatments. When will @potus @cmsgov end health plan tactics that bully & deny sick patients care? https://t.co/DZREVjCN9h

No Patient Left Behind

NPLB_org

Ditch @ConanOBrien & @SmartLess today. Recommended drive/subway (metro/T) time listening w/@PeterKolchinsky @RACapital @NPLB_org & @njlittman to discuss his book “The Great American Drug Deal", the biotech social contract, & importance of biotech affordability & innovation. https://t.co/8C0xPQTJYC

No Patient Left Behind

NPLB_org

@JoshuaPCohen1 @icer_review @NICEComms @CADTH_ACMTS faulty & outdated math needs a complete overhaul beyond QALY. Read how it can be improved to include real-world patient & societal benefits (animation & ppt), not just interests of plan actuaries managing a plan year. https://t.co/jgJDsK2xHy

No Patient Left Behind

NPLB_org

Insurers use faulty cost-effectiveness (CEA) math to deny coverage and charge high co-pays—even for life-saving and life-improving treatments prescribed by a physician.

No Patient Left Behind

NPLB_org

We’re committed to using better, patient-centric and societal math through “generalized cost-effectiveness analysis” (GCEA). Check out our GCEA animation to learn more about the value of medicines. https://t.co/3MkjjBkrSP

No Patient Left Behind

NPLB_org

RT @ISPORJournals: Cost-effectiveness analyses should include price declines often accompanying loss of exclusivity. Leaving future prices…

No Patient Left Behind

NPLB_org

More evidence health plans use high OOPCs as strategy to deny care. "High out-of-pocket costs have largely been eliminated for screening mammography," yet "still serve as financial barriers to patients undergoing subsequent diagnostic tests" @loopcoalition https://t.co/L0JCWO3lMD

No Patient Left Behind

NPLB_org

Tiramisù-y Icebox Cake Recipe | Bon Appétitc ck # https://t.co/UfPstbpHx6

No Patient Left Behind

NPLB_org

ICYMI: ICER-AHIP deal to expand influence of faulty, outdated CEA math on plan coverage (e.g. denial) & copay decisions is bad for patients. Check out our new animation to see how they get the math wrong & use it to limit access to prescribed treatments. https://t.co/WWsq65QBtN https://t.co/YRdBKjvGa9

No Patient Left Behind

NPLB_org

For insurance to really be insurance, it should fully cover the drugs your doctor prescribes when you’re sick—without high out-of-pocket costs. After all, what are premiums for? https://t.co/QAmA6trmIf

No Patient Left Behind

NPLB_org

RT @DrugChannels: Powerful 🧵 from @PeterKolchinsky

No Patient Left Behind

NPLB_org

Thank you @drugchannels! When medicines are worth it & right for you, insurance should cover them without high out-of-pocket costs. Our GCEA animation shows how insurers & HTA entities use faulty, outdated math to limit patient access to prescribed therapies. https://t.co/YzDRo935d9

No Patient Left Behind

NPLB_org

Orphan disease exemptions under the #IRA apply to drugs with one indication, whereas small company exemptions only apply for two years—incentivizing better marketing, not increased spending on innovation. Learn more: https://t.co/ENArnPGoZE

No Patient Left Behind

NPLB_org

Continued biopharmaceutical innovation is needed for the millions of patients living without cures or effective treatments. That’s why we support insurance reform to preserve innovation and protect access to life-saving medicines. https://t.co/Mx394Aza42

No Patient Left Behind

NPLB_org

RT @TuftsCEVR: In a new paper, @jcohen1964 found that accounting for generic pricing can make cost-effectiveness ratios substantially more…

No Patient Left Behind

NPLB_org

“First Responders” are people who are prepared to advocate for healthcare reform and ensure biotech affordability and innovation. Sign up today: https://t.co/Tu7lhfzoSN

No Patient Left Behind

NPLB_org

@BowTiedBiotech @JebKeiper @NimbusTx Best way to simply fix IRA is begin Medicare price setting for small molecules at 13 years after FDA approval. Proposal would not delay implementation timeline. Can read more here: https://t.co/AaI0yWnIOM

No Patient Left Behind

NPLB_org

@JebKeiper @NimbusTx Thank you for your leadership @JebKeiper & @NimbusTx. @MassBio @RepRichardNeal Smart modification to IRA in Medicare extenders package can preserve small molecule innovation, ensure patient Rx affordability, & win new support for law's implementation.

No Patient Left Behind

NPLB_org

“Inflation in the medical sector will mean higher premiums, deductibles, and out-of-pocket costs.” Read how insurance companies are profiting from medical inflation at the expense of you and me. https://t.co/820WP19tF5

No Patient Left Behind

NPLB_org

“@IQVIA_US shows that OOP on insulin declined $500 million since 2018, but that’s nowhere near growth in value of the rebate growth over the same time.” Wow. What are premiums for if vertically integrated insurers/PBMs/specialty keep Rx discounts for themselves vs sick customers? https://t.co/wovRZIfgfw

No Patient Left Behind

NPLB_org

@costplusdrugs @isabellacueto "Medicare could have saved up to $3.6 billion in 2020 — or 37% of the $9.6 billion spent on 77 of 89 different prescription medicines." @cmsgov Imagine how much beneficiaries could have saved in corresponding reduced copays! https://t.co/7l8ig2XEiK https://t.co/JquxRi6urp

No Patient Left Behind

NPLB_org

Thank you @G17Esiason for highlighting @statnews need for insurance & PBM reforms. Plans must ensure prescribed therapies approved for coverage are affordable to patients — not rebates for steering $$ to vertically integrated cos. What are premiums for anyway? @loopcoalition @FTC https://t.co/NPrt4hsdyN

No Patient Left Behind

NPLB_org

@PeterKolchinsky “We’ll always owe Ukraine. Let’s send more aid.” @POTUS @SecBlinken @SenatorMenendez https://t.co/quOmpHGtoa

No Patient Left Behind

NPLB_org

@ThePFID “Urgent public health needs demand passage of the PASTEUR Act.” https://t.co/luYy4oXoav

No Patient Left Behind

NPLB_org

Easy to agree w/@G17Esiason “Why have people been gaslighted to believe benefit design isn’t the problem?” What are premiums for anyway if not to make sure prescribed treatments are affordable to patients? @loopcoalition @FTC @CMSGov https://t.co/2afx7NwOIL

No Patient Left Behind

NPLB_org

RT @loopcoalition: Millions of Americans who enroll for health insurance this fall still won’t be able to easily afford the health care the…

No Patient Left Behind

NPLB_org

RT @rapport_bio: Learn from experts in the innovator, policy, and investor communities as they provide analysis for biotech leaders on the…

No Patient Left Behind

NPLB_org

Read @rapport_bio @PeterKolchinsky on how “IRA law already is influencing small molecule & orphan drug R&D prioritization.” 9 years is too short. Govt. price setting at 13 yrs for pills & injectables can restore vital R&D incentives & parity. Critical fix can pay for itself! https://t.co/ij9UYwgpgZ

No Patient Left Behind

NPLB_org

“Black adults who have had health care debt are twice as likely as white adults with such debt to say they’ve been denied care because they owe money.” Powerful @NoamLevey data & reporting. @loopcoalition https://t.co/Kdlga9FmoH

No Patient Left Behind

NPLB_org

Powerful @NoamLevey @KHNews @NPRHealth reporting. “Diagnosed w/ cancer 5 years ago, Reed underwent surgery & chemotherapy. Although she had health insurance through work, she was left w/ close to $10,000 in medical bills she couldn’t pay.” What are premiums for? @loopcoalition https://t.co/Wlvy4BNjZ1

No Patient Left Behind

NPLB_org

@TuftsCEVR report quantifies how most traditional CEAs ignore real world patient, family, & societal values. Registry baseline a call to action. Time to improve faulty CEA math that govts & plans use to deny Rx access. Learn how to do better CEA math @ https://t.co/MOCX5uKvNc https://t.co/VQB6BMMBXN

No Patient Left Behind

NPLB_org

“Although UNH’s profits have increased exponentially over the past 10 years, it had nearly *400,000 FEWER* people enrolled in health plans serving people in the private sector on September 30, 2022, than on September 30, 2012.” @wendellpotter https://t.co/bsx9AsBkfw

No Patient Left Behind

NPLB_org

@FTC @BrooksLaSureCMS 👀@DrugChannels visual on how plans can use vertical integration to shift regulated MA PMPM $$ to unregulated sister cos. Scheme maximizes parent org revenues, profits, & stock prices w/o passing intended savings to taxpayers or benes. Fix in'24 rate notice! https://t.co/9KdY9MjcOc

No Patient Left Behind

NPLB_org

The IRA aimed to reduce drug costs, but key provisions could create a negative environment for investment and innovation. Watch our recent webinar exploring the impacts of Part D Redesign, drug “negotiation,” and inflation rebates on innovators & patients: https://t.co/ENArnPoNB4

No Patient Left Behind

NPLB_org

@realclearhealth "Insurance companies and industry middlemen should not be able to undermine this [doctor-patient] relationship to ensure greater profits. Copay assistance ‘adjustment’ policies need to end." https://t.co/gP8KgG12D9

No Patient Left Behind

NPLB_org

@costplusdrugs "using business as a force for positive change. Helping companies reduce their employee health insurance costs means they can use that money for other innovations & drive economic growth" ICYMI @BizRoundtable @USChamber @ERISAIndCmte https://t.co/RIkDOXSIou

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: @barttels2 @AngryCardio @LifeSciVC @NPLB_org Considering that critics give no credit for genericization, the trillions…

No Patient Left Behind

NPLB_org

Learn why we should prioritize generalized cost-effectiveness analysis (GCEA) over the outdated math used by ICER, NICE, and their peers. https://t.co/ivoUn53wWN

No Patient Left Behind

NPLB_org

ICYMI @ERISAIndCmte @USChamber @BizRoundtable Market disruption by @costplusdrugs = huge generic Rx savings for self-insured employers & lower out-of-pocket costs (and premiums?) for employees. Employer decision-making can speed #PBMReform https://t.co/NKFvYjDfQY

No Patient Left Behind

NPLB_org

@G17Esiason “Congress needs to support antibiotic development with no-nonsense legislation.” https://t.co/2pSYiEimhN

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: Congress is on the verge of gutting cancer & Alzheimer’s R&D w/ a few careless lines in reconciliation bill b/c seemin…

No Patient Left Behind

NPLB_org

“But patients are increasingly on the hook for large bills because of deductibles and other health plan cost sharing.” What are insurance premiums for if plans still leave patients on the hook for large bills and costly medical debts? @loopcoalition https://t.co/sb7Esgi5RX

No Patient Left Behind

NPLB_org

RT @rapport_bio: The new Senate drug bill is bad for innovation and "falls short of a generational opportunity to meaningfully lower Medica…

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: The approach @MorningstarInc relies on is demonstrably absurd and oversimplified. It pretends drugs don’t go generic,…

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: @johnzabroski @MorningstarInc @NPLB_org https://t.co/3aupv9c4Ao

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: To learn more about the complexities of valuing medicines (figuring out if they are "worth it"), No Patient Left Behin…

No Patient Left Behind

NPLB_org

RT @loopcoalition: NEW from @NoamLevey at @KHNews: Former Kaiser CEO George Halvorson cited the growth of high-deductible health insurance…

No Patient Left Behind

NPLB_org

RT @KHNews: New KHN-@NPR investigative series #DiagnosisDebt examines pervasive medical debt hidden as credit card balances, loans from fam…

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: For anyone who heard of the biotech “Downturn Concepts/Tools” webinar Tess Cameron and I hosted with Dan Lepanto of @S…

No Patient Left Behind

NPLB_org

RT @rapport_bio: With all the hype around Covid and monkeypox, it’s easy to forget that viruses aren’t the only infectious game in town. So…

No Patient Left Behind

NPLB_org

@GoodRx @benefitspro "It’s about affording routine drugs for chronic conditions & finding that their insurance doesn’t cover what it used to... Americans are paying more out of pocket.” Join fight for insurance reform @NPLB_org @loopcoalition https://t.co/1R438Tfc3d

No Patient Left Behind

NPLB_org

RT @PeterKolchinsky: This little girl, like many, knows more about American healthcare than she should. We tell her story and offer specifi…

No Patient Left Behind

NPLB_org

RT @SecBecerra: More Americans than ever are gaining the affordable health coverage they need and deserve, thanks to the American Rescue Pl…

No Patient Left Behind

NPLB_org

Informative @PeterKolchinsky @michael_gilman @TheWellNews op-ed makes case for BBB Rx fixes that lower Part D beneficiary copays & deductibles and preserve small-molecule R&D. Congress can achieve affordability & innovation @NPLB_org https://t.co/efg59lhEc0

No Patient Left Behind

NPLB_org

Interesting read about how small-molecule R&D is crucial to biopharma innovation on behalf of patients and society. Achievable pro-beneficiary, pro-innovation, and pro-payer BBB fixes are worth it for us all. https://t.co/sKbquyCV4h

No Patient Left Behind

NPLB_org

RT @loopcoalition: Cancer patients are paying higher and higher out-of-pocket costs for treatment and, according to a report from @American…

No Patient Left Behind

NPLB_org

RT @PattyMurray: For too long, countless patients have been surprised by exorbitant bills for care they thought was covered by their insura…

No Patient Left Behind

NPLB_org

Thank you @BethWaldron & @PeterKolchinsky for sharing facts about the fight to access doctor-prescribed therapies for 150K US blood clot patients. Unhealthy side-effect of plan/pbm vertical integration. Not so Happy New Year from @cvshealth 🤔 ICYMI @KarenSLynch @loopcoalition https://t.co/rnvi9XyGRP

No Patient Left Behind

NPLB_org

@mikejopek's dad's "expensive insurance says his medicine is not covered under the drug plan he pays hundreds in monthly premiums. It’s a different tier they say." Join the fight for insurance reforms that lower out-of-pocket costs @NPLB_org @loopcoalition https://t.co/4nvOjURbIf

No Patient Left Behind

NPLB_org

RT @G17Esiason: The CDC throwing subtle shade at hospital pricing and the OOP cost of care to people. Love that for our federal public heal…

No Patient Left Behind

NPLB_org

RT @rachel_roubein: Biden admin repeals Trump's most-favored nation drug pricing rule, a pilot project to tie prices of some drugs in Medic…

No Patient Left Behind

NPLB_org

RT @EBDgroup: It’s no secret that the biopharma industry is facing headwinds. But will Build Back Better be all bad? Register today to view…

No Patient Left Behind

NPLB_org

“[Health plan network] terminations throw tens of thousands of patients into the difficult position of choosing between much higher out-of-pocket costs or leaving a trusted physician and hospital.” https://t.co/j2bEKBl4Rn

No Patient Left Behind

NPLB_org

@NPRHealth: "This is a family under stress-a premature baby, dad w/a cancer diagnosis, a hospital saying they need to pay $45,000 a month. What did they do?" What are premiums for if insurers won't pay medically necessary claims? Join the fight @NPLB_org https://t.co/Muoy6eHpVx

No Patient Left Behind

NPLB_org

@KHN: We spend ~12M hrs/wk calling our health plan (It also causes customer burnout). Which is more cumbersome, time consuming, and confusing -- speaking with your health plan or your mobile phone company? https://t.co/rBP89C8wEO

No Patient Left Behind

NPLB_org

@NPRHealth @Reportersteph highlight apathy of insurers toward patient out-of-pocket costs. When health plans wouldn't pay a $550K tab for a newborn's ICU care, mom was given a "chance" to pay ~$46k/month. Join the fight for reform @loopcoalition @NPLB_org https://t.co/X1tr4M4mM9

No Patient Left Behind

NPLB_org

RT @NPRHealth: Bill of the Month: $45,843 a month for a year for baby's NICU stay https://t.co/E9yIrDS4rW